PP405

Etki Mekanizması

PP405 is a dual inhibitor of the mitochondrial pyruvate carrier complex, targeting both the MPC1 and MPC2 subunits. Under normal conditions, the MPC transports pyruvate from the cytoplasm into the mitochondrial matrix, where it enters the tricarboxylic acid (TCA) cycle for oxidative metabolism. In hair follicle stem cells (HFSCs), this standard metabolic pathway is associated with quiescence and dormancy. By blocking MPC1/MPC2, PP405 prevents pyruvate from entering the mitochondria, causing it to accumulate in the cytoplasm. This pyruvate buildup stimulates lactate dehydrogenase (LDH) activity, which converts pyruvate to lactate, shifting the cell's metabolic profile toward aerobic glycolysis. This metabolic reprogramming mimics the signaling environment that naturally triggers HFSCs to exit quiescence and re-enter the cell cycle. The activated stem cells then initiate a new anagen (growth) phase in dormant hair follicles. Critically, this mechanism is entirely independent of the androgen/DHT pathway targeted by finasteride and dutasteride, and distinct from the vasodilatory effects of minoxidil, meaning PP405 could be effective regardless of a patient's androgen status.